Antidepressant use during pregnancy: A critical systematic review of the literature

Current Drug Safety

Volumn 5, Issue 2, 2010, Pages 153-170

  Simoncelli, Mariève ^a   Martin , Brigitte Zoé ^a   Bérard, Anick ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Antidepressants; Birth defects; Child development; Low birth weight; Pregnancy; Prematurity

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

ANENCEPHALUS; ANXIETY DISORDER; ARTICLE; BONE MALFORMATION; CARDIOVASCULAR MALFORMATION; CHILD DEVELOPMENT; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; DEPRESSION; EMBRYO DEVELOPMENT; EYE MALFORMATION; FETUS OUTCOME; GASTROINTESTINAL MALFORMATION; HEART RIGHT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPOSPADIAS; LIMB DEFECT; LIMB MALFORMATION; LOW BIRTH WEIGHT; MUSCLE MALFORMATION; NEWBORN CARE; OMPHALOCELE; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; SMALL INTESTINE OBSTRUCTION; SYSTEMATIC REVIEW;

EID: 77950811682     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610790936114     Document Type: Article

References (75)

1. Pearlstein T. Perinatal depression: treatment options and dilemmas. J Psychiatry Neurosci 2008; 33(4): 302-318
2. Pearson KH, Nonacs RM, Viguera AC, et al. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry 2007; 68(8): 1284-1289
3. Ross LE, McLean LM. Anxiety disorders during pregnancy and the postpartum period: a systematic review. J Clin Psychiatry 2006; 67(8): 1285-1298
4. Acs N, Banhidy F, Horvath-Puho E, Czeizel AE. Maternal panic disorder and congenital abnormalities: a population-based casecontrol study. Birth Defects Res A Clin Mol Teratol 2006; 76(4): 253-261
5. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49(11): 726-735 (Pubitemid 40100521)
6. Hollins K. Consequences of antenatal mental health problems for child health and development. Curr Opin Obstet Gynecol 2007; 19(6): 568-572
7. Gold KJ, Marcus SM. Effect of maternal mental illness on pregnancy outcomes. Expert Rev Obstet Gynecol 2008; 3(3): 39-401.
8. Talge NM, Neal C, Glover V. Antenatal maternal stress and longterm effects on child neurodevelopment: how and why? J Child Psychol Psychiatry 2007; 48(3-4): 245-261
9. Littleton HL, Breitkopf CR, Berenson AB. Correlates of anxiety symptoms during pregnancy and association with perinatal outcomes: a meta-analysis. Am J Obstet Gynecol 2007; 196(5): 424-432
10. Alder J, Fink N, Bitzer J, Hosli I, Holzgreve W. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? a critical review of the literature. J Matern Fetal Neonatal Med 2007; 20(3): 189-209.
11. Rice F, Jones I, Thapar A. The impact of gestational stress and prenatal growth on emotional problems in offspring: a review. Acta Psychiatr Scand 2007; 115(3): 171-183
12. Rosa F. Medicaid antidepressant pregnancy exposure outcomes. Reprod Toxicol 1994; 8(5): 444-445
13. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.[see comment]. JAMA 1998; 279(8): 609-610
14. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure.[see comment]. Am J Psychiatry 2002; 159(12): 2055-2061
15. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142(4): 402-408
16. Kallen BAJ, Otterblad OP. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003; 17(3): 255-261
17. Kallen B. Fluoxetine use in early pregnancy.[comment]. Birth Defects Res B Dev Reprod Toxicol 2004; 71(6): 395-396
18. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106(6): 1289-1296
19. Kallen B, Otterblad OP. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006; 21(3): 221-222
20. Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17(6): 701-704
21. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356(26): 2684-2692
22. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy.[see comment]. Pharmacoepidemiol Drug Saf 2007; 16(10): 1086-1094
23. Kallen B. The safety of antidepressant drugs during pregnancy. Expert Opin Drug Saf 2007; 6(4): 357-370
24. Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007; 27(6): 607-613
25. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356(26): 2675-2683
26. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66(5): 695-705.
27. Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008; 115(2): 283-289
28. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008; 83(1): 68-76.
29. Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br Psychiatry 2008; 192(5): 344-350
30. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269(17): 2246-2248 (Pubitemid 23120281)
31. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine.[see comment]. N Engl J Med 1996; 335(14): 1010-1015
32. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158(10): 1728-1730
33. Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003; 48(2): 106-110
34. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192(3): 932-936 (Pubitemid 40311292)
35. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 2005; 193(6): 2004-2009 (Pubitemid 41737626)
36. Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006; 67(8): 1280-1284
37. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80(1): 18-27.
38. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations.[see comment]. Pharmacoepidemiol Drug Saf 2007; 16(10): 1075-1085
39. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16(5): 474-484
40. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165(6): 749-752
41. Crombie DL, Pinsent RJ, Fleming D. Imipramine in pregnancy. Br Med J 1972; 1(5802): 745.
42. Sim M. Imipramine and pregnancy. Br Med J 1972; 2(5804): 45.
43. Kuenssberg EV, Knox JD. Imipramine in pregnancy. Br Med J 1972; 2(5808): 292.
44. Rachelefsky GS, Flynt JW, Jr, Ebbin AJ, et al. Possible teratogenicity of tricyclic antidepressants. Lancet 1972; 1(7755): 838-839
45. Anonymous. Tricyclic antidepressants and limb reduction deformities. a further communication from the Australian Drug Evaluation Committee. Med J Aust 1973; 1(15): 768-769
46. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998; 105(8): 882-889
47. Hostetter A, Stowe ZN, Strader JR Jr, McLaughlin E, Llewellyn A. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 11(2): 51-57
48. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89(5 Pt 1): 713-718
49. Result Summary for EPIP083 (Final Report). www.gsk.com [Accessed on Dec 22, 2008].
50. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48(10): 996-1000.
51. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine.[see comment]. Arch Pediatr Adolesc Med 2002; 156(11): 1129-1132
52. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy.[see comment]. Arch Pediatr Adolesc Med 2004; 158(4): 312-316
53. Suri R, Altshuler L, Hendrick V, Rasgon N, Lee E, Mintz J. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 2004; 7(3): 193-200.
54. Ferreira E, Carceller AM, Agogue C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007; 119(1): 52-59
55. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008; 192(5): 338-343
56. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007; 164(8): 1206-1213
57. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63(8): 898-906.
58. Ericson A, Kallen B, Wiholm BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55(7): 503-508 (Pubitemid 29446550)
59. Ramos E, St-Andre M, Rey E, Oraichi D, Bérard A. Association between antidepressant use during pregnancy and infants born small-for-gestational-age. Obstet Gynecol 2010 (submitted).
60. Cissoko H, Swortfiguer D, Giraudeau B, Jonville-Bera AP, Autret- Leca E. Neonatal outcome after exposure to selective serotonin reuptake inhibitors late in pregnancy. Arch Pediatr 2005; 12(7): 1081-1084 (Pubitemid 40835224)
61. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication.[see comment]. Am J Obstet Gynecol 2003; 188(3): 812-815
62. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21(2): 157-171
63. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336(4): 258-262
64. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72(2): 184-191
65. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159(11): 1889-1895
66. Mortensen JT, Olsen J, Larsen H, Bendsen J, Obel C, Sorensen HT. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol 2003; 18(8): 769-771
67. Misri S, Reebye P, Kendrick K, et al. Internalizing behaviors in 4- year-old children exposed in utero to psychotropic medications. Am J Psychiatry 2006; 163(6): 1026-1032
68. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007; 161(1): 22-29
69. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293(19): 2372-2383 (Pubitemid 40676760)
70. Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol 2008; 28(3): 334-339
71. Kallen B, Olausson PO. Maternal use of selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17(8): 801-806
72. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.[see comment]. N Engl J Med 2006; 354(6): 579-587 (Pubitemid 43209105)
73. Ramos E, Oraichi D, Rey E, Blais L, Berard A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 2007; 114(9): 1055-1064
74. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198(2): 194: 1-5.
75. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295(5): 499-507.